Results 71 to 80 of about 743 (109)

Brivaracetam and rufinamide combination increased seizure threshold and improved neurobehavioral deficits in corneal kindling model of epilepsy

Animal Models and Experimental Medicine
Background Besides seizures, a myriad of overlapping neuropsychiatric and cognitive comorbidities occur in patients with epilepsy, which further debilitates their quality of life.
Awais Sattar, Zohabia Rehman, Hammad Murtaza, Waseem Ashraf, Tanveer Ahmad, Faleh Alqahtani, Imran Imran   +6 more
doaj   +1 more source

Review of the article „Method Development and Validation of a Novel UHPLC Coupled with MS/MS Method for the Estimation of Brivaracetam in Human (K2EDTA) Plasma Samples and its Application to Pharmacokinetic Study“, verified by Publons, Web of Science [PDF]

, 2021
Background: Brivaracetam is a novel antiepileptic drug, approved clinically for the treatment of partial onset seizures in adults and adolescents. It has some abuse potential and assigned to Schedule V category under the Controlled Substance Act by the ...
Jovanović, Tamara
core  

Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV‐add study

Epilepsia Open
Objective To evaluate the effectiveness and safety of brivaracetam (BRV) as an add‐on therapy in patients with focal onset seizures who did not achieve seizure freedom with antiseizure medication (ASM) monotherapy in routine clinical practice.
Pedro J. Serrano‐Castro, Fernando Caballero‐Martínez, Francisco J. Campos‐Lucas, Daniel Campos‐Fernández, María José deAguilar‐Amat, Alberto García, Ariadna Gifreu, Irene Santamaría‐Rodríguez, Juan José Poza, Manuel Toledo‐Argany, Grupo de Investigadores Colaboradores   +10 more
doaj   +1 more source

An evidence-based meta-analysis on the use of brivaracetam in treating seizures in real-world clinical practice

Frontiers in Pharmacology
ObjectiveThe study aimed to evaluate the clinical efficacy and safety of brivaracetam (BRV) as monotherapy or adjuvant therapy for adults with seizures.MethodsObservational studies of BRV were systematically searched. We estimated the pooled incidence of
Yu Zhang, Yu Zhang, Huihui Liu, Xin Wang, Zhiqiang Zhao, Hong Su, Yanjun Ma, Jie Zhao, Qingshan Wang, Qingshan Wang, Liyan Hou, Liyan Hou   +11 more
doaj   +1 more source

How does brivaracetam compare with placebo for reducing seizures in adults and adolescents with drug-resistant epilepsy?

, 2019
Adults and adolescents with drug‐resistant epilepsy probably benefit from treatment with brivaracetam, but a few may experience adverse events leading to withdrawal from treatment.Compared with placebo for adults and adolescents with drug‐resistant ...
Ciapponi, Agustín
core   +1 more source

Brivaracetam-Related Neurological Decline in a Patient With Complex Medical History

Introduction: Brivaracetam is a newer anticonvulsant that is a propyl analogue of levetiracetam. The medication was initially approved in 2016 as an add-on treatment and was later approved in 2018 as monotherapy for treatment of partial-onset seizures. A
Cherabuddi, Medha R, Fram, Farah, Abu Sayf, Alaa, Aljbour Almajali, Dina, Ayyad, Asem   +4 more
core   +1 more source

Demonstration of the effect of brivaracetam on an experimental epilepsy model

, 2018
Background/aim: The aim of this study was to investigate the effects of valproic acid (VPA) and a new-generation antiepileptic drug called brivaracetam (BRV) on the brain damage occurring after status epilepticus (SE) in ...
ÇETİNER, MUSTAFA, AYDIN, HASAN EMRE
core   +1 more source

Increased Libido Following Brivaracetam Initiation: A Case Report of Temporal Lobe Epilepsy

Neuropsychopharmacology Reports
Background Sexual dysfunction is a common comorbidity in patients with epilepsy; it correlates with seizure frequency and right temporal lobe epilepsy and affects quality of life (QOL).
Toru Horinouchi, Taiki Matsuyama, Mayusa Mito, Yuichi Nakamura, Takahiro A. Kato   +4 more
doaj   +1 more source

Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal‐onset seizures: A phase III randomized, double‐blind, placebo‐controlled trial

Epilepsia Open
Objective Evaluate efficacy, safety, and tolerability of adjunctive brivaracetam (BRV) in adult Asian patients with focal‐onset seizures (FOS). Methods Phase III, randomized, double‐blind, placebo‐controlled study (EP0083; NCT03083665) evaluating BRV 50 ...
Yushi Inoue, Somsak Tiamkao, Dong Zhou, Leonor Cabral‐Lim, Kheng Seang Lim, Shih‐Hui Lim, Jing‐Jane Tsai, Brian Moseley, Lin Wang, Weiwei Sun, Yoshinobu Hayakawa, Hiroshi Sasamoto, Tomonobu Sano, Carrie McClung, Almasa Bass   +14 more
doaj   +1 more source

Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children

Frontiers in Pharmacology
ObjectiveThe present study was a retrospective pharmacovigilance analysis to identify pharmacovigilance signals of psychiatric adverse events (AEs) associated with the clinical use of third-generation antiepileptic drugs (AEDs) in children, thereby ...
Wenfang Sun, Yali Li, Binbin Xia, Liushui Li, Jing Chen, Yang Liu, Jingyao Pang, Fang Liu, Hua Cheng   +8 more
doaj   +1 more source